Request Demo

Last update 07 Mar 2026

Lixisenatide

Last update 07 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide, DesPro38Exendin-4(1-39)-Lys6-NH2, Lixisenatide (JAN/USAN/INN)

+ [13]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication

Acute Coronary SyndromeDiabetes Mellitus, Type 1Gastroparesis+ [4]

Originator Organization

Zealand Pharma A/S

Active Organization

Sanofi-Aventis Canada, Inc.Sanofi KK

Sanofi-Aventis U.S. LLC

Inactive Organization

Sanofi

Sanofi Winthrop Industrie SASanofi-Aventis Recherche & Développement SA

+ [3]

License Organization

Sanofi

Royalty Pharma Plc

Zealand Pharma A/S

Drug Highest PhaseApproved

First Approval Date

European Union (31 Jan 2013),

Diabetes Mellitus, Type 2

Regulation-

Structure/Sequence

Sequence Code 25682

Source: *****

Clinical Trials associated with Lixisenatide

NCT07173712

/ Not yet recruitingPhase 4IIT

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Hypoglycemic Agents: A Multicenter, Open-Label, Randomized Controlled Study

Failure of oral antidiabetic drugs (OADs) is a frequent challenge in patients with type 2 diabetes mellitus (T2DM), and inadequate long-term glycemic control substantially increases the risk of diabetic complications. Short-term intensive insulin therapy (SIIT) is an established approach to mitigate glucotoxicity; however, the optimal strategy to sustain long-term glycemic benefits after SIIT in T2DM patients with OAD failure remains unclear. To address this gap, we designed a randomized controlled trial to evaluate subsequent treatment options, aiming to identify a simple and effective regimen for patients with poor glycemic control who undergo SIIT.
A total of 324 eligible patients will be enrolled. After screening, previous antidiabetic regimens will be discontinued, and patients will be randomly assigned to the SIIT- iGlarLixi group (A), the SIIT-IDegAsp group (B), or the SIIT-iGlar group (C). All patients will be hospitalized for short-term insulin pump therapy, followed by 24 weeks of treatment: group A with insulin glargine/lixisenatide, group B with insulin degludec/aspart, and group C with insulin glargine U300 plus metformin. During the extension follow-up period, patients in all groups may either continue their assigned regimen or return to their original pre-study therapy. A total of 10 clinic visits are scheduled for each patient throughout the study.
Primary endpoint is proportion of patients achieving glycosylated hemoglobin A1C <7% at 24 weeks.Secondary endpoints include proportion of patients achieving glycosylated hemoglobin A1C <6.5% at 24 weeks; differences in weight gain, hypoglycemic events among treatment groups, and differences in proportion of patients continuing the assigned regimen, glycemic control and body weight at the extension follow-up period.

Start Date15 Mar 2026

Sponsor / Collaborator

Sun Yat-Sen University

NCT07117240

/ Enrolling by invitationPhase 4IIT

Efficacy of Treatment Strategies for Steroid-induced Diabetes - a Comparison of GLP-1 Receptor Agonist Plus Basal Insulin With Intensive Insulin Therapy

Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects. In the proposed research, the aim is to assess the metabolic efficacy and safety of fixed-ratio combination therapy (basal insulin + GLP-1 receptor agonist) compared to standard insulin therapy in patients with SID. In a selected group of patients, a randomised clinical trial would be conducted to assess the potential benefits of GLP-1 receptor agonists in the management of SID.

Start Date10 Jul 2025

Sponsor / Collaborator

Warszawski Uniwersytet Medyczny

CTRI/2024/10/075222

/ Not yet recruitingPhase 4

A Multicentre Phase IV single arm clinical trial to evaluate the safety and efficacy of a fixed ratio combination of Insulin Glargine and Lixisenatide in adult patients with Type 2 diabetes who are sub optimally controlled on oral anti-hyperglycemic drugs and/or basal Insulin/GLP-1 RA - iGlarLixi Phase 4 study in India

Start Date28 Oct 2024

Sponsor / Collaborator

Sanofi Healthcare India Pvt Ltd.

100 Clinical Results associated with Lixisenatide

100 Translational Medicine associated with Lixisenatide

100 Patents (Medical) associated with Lixisenatide

506

Literatures (Medical) associated with Lixisenatide

01 Apr 2026·CURRENT OPINION IN NEUROBIOLOGY

The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease

Review

Author: Huot, Philippe ; Teil, Margaux

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.

01 Feb 2026·DIABETES OBESITY & METABOLISM

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Article

Author: Donnelly, Louise A. ; McCrimmon, Rory J. ; Singh, Katyayeni ; Pearson, Ewan R.

Abstract:

Aims:

Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage. We describe patterns across individual subclasses, and in overall class‐level models, we examined clinical characteristics associated with each category with particular interest in poor adherence and intolerance.

Materials and Methods:

We conducted an observational cohort study using electronic health records from the Scottish Care Information Diabetes Collaboration database, including individuals with type 2 diabetes who initiated a SGLT2i or GLP‐1RA. Each initiation was followed for 1 year and classified into five mutually exclusive groups: adherent, poor adherence and three discontinuation categories including a proxy for intolerance.

Results:

Among SGLT2is, poor adherence was more common in younger individuals, with greater socioeconomic deprivation, and higher HbA 1c , while intolerance was more frequent in older, leaner females and in those with prior genital thrush. For GLP‐1RAs, newer agents were associated with more favourable usage patterns. Poor adherence was more frequent with liraglutide, lixisenatide, and exenatide compared to semaglutide, and intolerance was more common with lixisenatide. In addition, poor adherence was associated with younger age and prior GLP‐1RA use, while intolerance was linked to lower BMI, female sex, and more advanced CKD.

Conclusions:

Distinct clinical and biochemical characteristics are associated with poor adherence versus discontinuation. Understanding these patterns is crucial for developing targeted strategies to improve sustained use, ultimately enhancing treatment outcomes for people with type 2 diabetes.

05 Dec 2025·MEDICINE

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation

Article

Author: Alsalmi, Bodour Saleh ; Alansari, Amal Omar ; Alamer, Bader ; Alharbi, Ahlam Saleem ; AlAjlan, Fadiyah Abdullah ; Alharbi, Abeer Abdullah ; Alzahrani, Basmah Saleh ; Alshehri, Khaled Mohammad ; Alatawi, Amirah M. ; Alhabib, Ali Tareq ; Almosfer, Waleed Abdulaziz

Background::

Glucagon-like peptide-1 receptor agonists (GLP-1 agonist) have revolutionized the treatment of obesity. However, regulatory agencies have reported an association with suicidality. To the best of our knowledge, this is the first meta-analysis to assess the association between GLP-1 agonist use, suicidal ideation, and suicide completion. We aimed to assess the same in patients with diabetes and obesity.

Methods::

We searched 6 databases for relevant articles, from the first published article to October 2024. The keywords used were GLP-1 agonists, suicidal ideation, suicide, suicidal behavior, semaglutide, liraglutide, tripeptide, exenatide, and lixisenatide. We identified 354 studies and 126 stands after the removal of duplicates, of which 23 were eligible, and only 12 studies were included in the final meta-analysis.

Results::

No significant statistical difference was found in suicidal ideations in patients on GLP-1 agonists compared to their counterparts on other obesity and diabetes drugs (odds ratio [OR], 1.0; 95% confidence interval [CI]: 1.0–1.0). No significant difference was observed between patients on GLP-1 agonists and their counterparts regarding complete suicide (OR, 1.77; 95% CI: 0.80–3.91). In a subgroup analysis, suicide was higher among patients on liraglutide compared to their counterparts on semaglutide (OR, 1.48; 95% CI: 1.17–1.89). No significant statistical difference was observed when comparing monjaro and semaglutide (OR, 0.98; 95% CI: 0.94–1.03).

Conclusion::

No significant statistical difference was found between GLP-1 agonists and other obesity and diabetes drugs regarding suicide/suicidal ideation. In a subgroup analysis, suicide was higher in patients on liraglutide compared to semaglutide, with no significant difference between semaglutide and monjaro. Randomized controlled trials that assess the association between GLP-1 agonists and suicidality are highly recommended.

News (Medical) associated with Lixisenatide

02 Mar 2026

·www.prnewswire.com

GLP-1 drugs associated with reduced need for emergency care for migraine

Drugs also related to lower use of drugs to stop, prevent attacks Highlights: For people with chronic migraine, starting GLP-1 drugs for conditions like diabetes may be associated with fewer emergency department visits. A preliminary study has found that people who started GLP-1 drugs were approximately 10% less likely than those who started topiramate to visit the emergency department over the following year. They were also about 14% less likely to be hospitalized for any reason during the year. This observational study does not prove that the drugs lower the need for emergency care for people with migraine. It only shows an association. MINNEAPOLIS, March 2, 2026 /PRNewswire/ -- For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online. The people with chronic migraine starting GLP-1 drugs were compared to people with chronic migraine who were starting topiramate, a drug commonly used to prevent migraine. The study does not prove that GLP-1 drugs lower the need for emergency care and additional drugs for migraine; it only shows an association. "People with chronic migraine often end up in the emergency room or they need to try several preventive medications before finding one that can work for them," said study author Vitoria Acar, MD, of the University of Sao Paulo in Brazil. "Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven't fully appreciated yet. " For the study, researchers analyzed a health-record database of people who had a chronic migraine diagnosis based on medical records. Chronic migraine is defined by having a headache on 15 or more days per month for at least three months, where at least eight of those days include typical migraine symptoms like throbbing pain, nausea, or light sensitivity. People who had started taking GLP-1 drugs for another condition within a year of a recorded diagnosis of chronic migraine were compared to people who started taking topiramate during that same period. The two groups were matched for factors such as age, body mass index, other health conditions, and prior migraine treatments. There were about 11,000 people in each group. The GLP-1 drugs studied included liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide and albiglutide. The researchers used medical records to track what happened to both groups over the following year. This included overall emergency department visits, hospitalizations, nerve block procedures, and any new prescriptions for medications used to stop or prevent migraine attacks. After accounting for differences in age, body weight, other health conditions, and prior migraine treatments, researchers found that 23.7% of people starting GLP-1 drugs visited the emergency department over the following year, compared with 26.4% of those starting topiramate. People starting GLP-1 drugs were about 10% less likely to have an emergency department visit, 14% less likely to be hospitalized, and about 13% less likely to undergo a nerve block procedure or receive a triptan prescription compared with those taking topiramate. They were also less likely to be prescribed new preventive migraine medications. Compared with people starting topiramate, those starting GLP-1 drugs were 48% less likely to start valproate, 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies, 35% less likely to start tricyclic antidepressants, and 23% less likely to start the class of drugs called gepants. There was no statistically significant difference between the two groups in the proportion of people starting beta blockers. "Chronic migraine often overlaps with metabolic and inflammatory conditions such as obesity, insulin resistance, sleep apnea and depression, which can make treatment more difficult," Acar said. "Early research is looking at whether GLP-1 drugs' anti-inflammatory and neurovascular effects could play a role in migraine treatment, not just through weight loss." Because this was an observational study, it cannot prove that GLP-1 drugs caused the lower need for emergency care or additional medications. Even though the groups were matched at the start, researchers could not measure things that changed over the year, such as weight loss, migraine severity, medication use patterns or lifestyle changes. These unmeasured factors could also have played a role. Further studies are needed. The study was supported by patient philanthropy and Miles for Migraine. Discover more about migraine at Brain & Life®, from the American Academy of Neurology. This resource also offers a website, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world's leading experts in brain health. Follow Brain & Life® on Facebook, X, and Instagram. The American Academy of Neurology is the leading voice in brain health. As the world's largest association of neurologists and neuroscience professionals with more than 44,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN's mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine. Explore the latest in neurological disease and brain health, from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn, and YouTube. SOURCE American Academy of Neurology 21% more press release views with Request a Demo

Clinical Result

02 Mar 2026

·www.drugs.com

AAN: GLP-1 Receptor Agonist Initiation for Chronic Migraine Tied to Improved Outcomes

MONDAY, March 2, 2026 -- For people with chronic migraine (CM), taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with fewer emergency department visits and hospitalizations overall and less need for medications used to stop and prevent migraine attacks, according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 18 to 22 in Chicago. Vitoria Acar, from the University of Sao Paulo in Brazil, and colleagues compared health care utilization, triptan use, and preventive-treatment escalation following initiation of a GLP-1 RA versus topiramate in adults with CM. The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate. The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87). GLP-1 RA initiators also had a lower risk for initiation of tricyclic antidepressants (RR, 0.65), valproate (RR, 0.52), gepants (RR, 0.77), calcitonin gene-related peptide monoclonal antibodies (RR, 0.58), and serotonin-norepinephrine reuptake inhibitors (RR, 0.80). For beta-blocker initiation, there were no significant differences observed. "Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven’t fully appreciated yet," Acar said in a statement. Press Release More Information

Clinical ResultAACR

11 Dec 2025

·pharma.economictimes.indiatimes.com

Regeneron drug wipes out residual multiple myeloma cells in small trial

London: A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest. Patients in the trial had received initial treatments that eliminated nearly all of their cancer cells. Usually, individuals with residual cancer cells , accounting for roughly half of patients treated with modern first-line drugs, would go on to receive high-dose toxic chemotherapy to destroy the remaining cancer cells and a bone marrow transplant to regrow healthy replacements. Study leader Dr. C. Ola Landgren of University of Miami Miller School of Medicine called the regimen "a brutal treatment." Instead, patients in the study received Regeneron's Lynozyfic, which was approved by the U.S. Food and Drug Administration in July for treatment of recurrent multiple myeloma. While most therapeutic antibodies attach to a single target, Lynozyfic attaches to two, CD3, a protein on T cells that destroys cancerous cells, and BCMA, a protein on multiple myeloma cells. None of the 18 trial participants who have so far completed up to six cycles of treatment with Lynozyfic have had detectable residual disease afterward on highly sensitive tests, the researchers reported at the American Society of Hematology annual meeting in Orlando. Ultimately they plan to enroll a total of 50 patients. Those who test negative for residual multiple myeloma cells can expect to live years longer without their cancer returning than those positive for it, Landgren said in a statement. "Based on my experience, I would predict that after having such a good response after such a short time, the disease most likely could stay away for many years," he said. "Could it never come back in some patients? I would say it's possible." GLP-1 DRUGS DO NOT APPEAR TO CUT CANCER RISKS Widely used weight-loss medications from the class known as GLP-1s likely have little or no effect on risk for obesity-related cancers, a large study suggests, although longer follow-up is needed to be certain. Researchers analyzed data from 48 trials involving 94,245 participants with type 2 diabetes or overweight or obesity who were randomly assigned to receive GLP-1 drugs or a placebo. Results showed the drugs probably have little or no effect on risk for cancers of the thyroid, pancreas, colon and rectum, stomach, esophagus, liver, gallbladder, breast, ovaries, endometrium, kidneys, or the blood cancer multiple myeloma or the brain cancer meningioma, researchers reported in Annals of Internal Medicine. Twenty of the trials tested semaglutide, the main ingredient in Novo Nordisk's Ozempic, Wegovy, and Rybelsus. Ten tested Novo's liraglutide, sold as Victoza and Saxenda. Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, was tested in eight trials. The remaining 11 trials tested Sanofi's Adlyxin (sold as Lyxumia outside the U.S.), Lilly's Trulicity, or AstraZeneca's Byetta. Most of the studies were not designed to assess cancer risks or benefits, and for some outcomes the findings were of low certainty, the researchers acknowledged. Longer-term studies with cancer-specific end points are needed to clarify potential risks or protective effects of the medicines, the researchers said. PRE-TEEN SMARTPHONE OWNERSHIP LINKED WITH HEALTH RISKS Smartphone ownership in early adolescence is linked with higher risks for depression, obesity, and insufficient sleep, according to a large U.S. study. More than 10,500 youngsters from 21 states were surveyed annually between 2018 and 2021 and also screened for depression, obesity, and whether or not they were getting a full nine hours of sleep per night. By age 12, roughly two-thirds of the children owned a smartphone, researchers reported in Pediatrics. These young smartphone owners had a 31% higher risk of depression, a 40% higher risk of obesity, and a 62% higher risk of insufficient sleep compared to their peers who did not own smartphones, the researchers found. By age 13, those who hadn't owned a smartphone at age 12 but who had acquired one in the past year were 57% more likely to report symptoms of clinical depression and 50% more likely to be getting insufficient sleep, compared to children who still didn't own smartphones. The younger the age at which children acquired a smartphone, the greater their risk of obesity and insufficient sleep at age 13, the researchers also found. "Our findings suggest that we should view smartphones as a significant factor in teen health, approaching the decision to give a child a phone with care and considering potential impacts on their life and health," study leader Dr. Ran Barzilay of the Hospital of the University of Pennsylvania said in a statement. The study cannot prove the smartphones caused these problems, and the authors say the devices will not be associated with detrimental outcomes in every adolescent. "Rather, we advocate for thoughtful consideration of the health implications, balancing both positive and negative consequences," Barzilay said. "For many teens, smartphones can play a constructive role by strengthening social connections, supporting learning, and providing access to information and resources that promote personal growth," he added. (To receive the full newsletter in your inbox for free sign up here) (Reporting by Nancy Lapid; Editing by Bill Berkrot)

Drug ApprovalClinical ResultASH

100 Deals associated with Lixisenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D09729	Lixisenatide	A10BJ03	DB09265

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	European Union	Sanofi Winthrop Industrie SA	31 Jan 2013
Diabetes Mellitus, Type 2	Iceland	Sanofi Winthrop Industrie SA	31 Jan 2013
Diabetes Mellitus, Type 2	Liechtenstein	Sanofi Winthrop Industrie SA	31 Jan 2013
Diabetes Mellitus, Type 2	Norway	Sanofi Winthrop Industrie SA	31 Jan 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nutrition Disorders	Phase 3	Italy	Sanofi-Aventis Recherche & Développement SA	08 Feb 2013
Acute Coronary Syndrome	Phase 3	United States	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	China	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Japan	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Argentina	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Australia	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Austria	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Belarus	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Belgium	Sanofi	01 Jun 2010
Acute Coronary Syndrome	Phase 3	Brazil	Sanofi	01 Jun 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2025	Phase 3	Prostatic Cancer	-	GLP-1 receptor agonists (GLP-1RAs)	erzytojpld(xucnvhvelc) = nusavbasls nmivqfkjwg (auagdfscnz )	Negative	13 Feb 2025
				Placebo/non-GLP-1 RA regimens	erzytojpld(xucnvhvelc) = bqxszabouk nmivqfkjwg (auagdfscnz )
NCT03439943 (LIXIPARK, Pubmed \| N Engl J Med)	Phase 2	Parkinson Disease	156	Lixisenatide	igjbetksnj(yjlfnrxbaw) = Nausea occurred in 46% of participants receiving lixisenatide zgwdhkgdgd (cfekwxtkun ) View more	Positive	04 Apr 2024
				Placebo
NCT03439943 (LIXIPARK, Literature) Manual	Phase 2	Parkinson Disease	156	Lixisenatide	ssmdevxcvp(vwfnvkporj) = bayyerktep kphomgmcae (tswzakkjvo ) View more	Positive	03 Apr 2024
				Placebo	ssmdevxcvp(vwfnvkporj) = xxsucpdbwt kphomgmcae (tswzakkjvo ) View more
NCT03798054 \| NCT03798080 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2	-	iGlarLixi	ljfmehznkw(akcerndumx): P-Value = 11.45	-	30 Mar 2023
				Glargine 100 U/mL
NCT03798080 (LixiLan-L-CN, Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	426	iGlarLixi	hffcecjvtb(svujkbuthx) = msbkivfcok qcskrmzftf (dntbkbctea ) View more	Superior	28 Jun 2022
				insulin glargine	hffcecjvtb(svujkbuthx) = licixndukf qcskrmzftf (dntbkbctea ) View more
STAR.Ro (Pubmed) Manual	Not Applicable	Diabetes Mellitus, Type 2	901	Lixisenatide+Insulin glargine	eogkrmgrbm(eacbepvdxq) = rmsjdhpzln kxkvkwtthm (dsneopiqja, -1.4 to -1.2) View more	Positive	27 May 2022
NCT03798054 (LixiLan-O-AP, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	878	iGlarLixi	mkxhrgwfmc(tghdvjfaxf) = jmpyfvojfk qhgpqrrpnj (dctmjgygtq ) View more	Positive	19 Apr 2022
				Insulin glargine 100 U/mL	mkxhrgwfmc(tghdvjfaxf) = quahttsmeh qhgpqrrpnj (dctmjgygtq )
NCT02231658 (EASD2020)	Phase 1	Diabetes Mellitus, Type 2	57	Lixisenatide	jjbengrzcw(mgblxdjltd) = hssrdhmoex sgbdragkuk (deshlejkra ) View more	Positive	24 Sep 2020
				Liraglutide	jjbengrzcw(mgblxdjltd) = dftyatrlhk sgbdragkuk (deshlejkra )
NCT02231658 (Pubmed \| Diabetes Care)	Phase 1	Diabetes Mellitus, Type 2	57	Lixisenatide	sphaxxmtxz(aqxgpjiojn) = siaficzxbx zosfdqhvrb (fmlxmhetvx, -40.6, - 0.8) View more	-	09 Jul 2020
				Liraglutide	nclgpzmcsy(dvrmhhjruj) = fbqodioceo mwdjiheput (ipmrjshcxd, 3 - 46)
NCT02640118 (Pubmed \| Diabetologia)	Not Applicable	Diabetes Mellitus	12	Lixisenatide	heybqpdvgj(hkgyqgcngs) = bipsppmrgh brvxunpflo (ffspvrekys ) View more	-	01 Jul 2020
				Placebo	heybqpdvgj(hkgyqgcngs) = gophgnvmid brvxunpflo (ffspvrekys ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis